Gagua M. Effectiveness of complex treatment of ovarian cancer patients with epigenetic defects of RASSF and GST genes

On the basis of investigation results of 221 ovarian cancer patients of IC-IV stage (152 ovarian cancer patients with methylation and 68 patients without RASSF and GST genes methylation) and 40 patients with benign ovarian tumor, the following connection between morphological characteristics of cancer tissue, ovarian cancer clinical course and RASSF and GST genes methylation presence has been determined; RASSF gene application as additional criterion of early and dif-diagnostics of ovarian tumors has been substantiated; and the ways of results increase of ovarian cancer patients treatment have been shown. Reliable difference of RASSF gene methylation frequency in blood serum of patients with benign ovarian tumor (5%) and ovarian cancer of IC stage (26,3%) explains that criterion availability for early diagnostics of ovarian cancer. It has been proved, RASSF gene methylation correlates with histological structure, differentiation degree, more proliferative activity of ovarian tumors, and it is an independent, reliable negative prognostic factor for ovarian cancer patients. It has been identified, RASSF and GST genes methylation determination in ovarian cancer patients of III-IV stage can be used for a choice of the first stage of treatment and polychemotherapy regimen: in case of RASSF gene methylation, less recurrence frequency arises in the use of neoadjuvant polychemotherapy at the first stage of treatment (72% of cases in comparison with 89,6% ones in the use of cytoreductive surgery, p<0,05); in case of GST gene methylation, there is an expediency of cytoreduction carrying-out at the first stage (70,3% in comparison with 95,0% of cases in the use of neoadjuvant polychemotherapy, p<0,05). Key words: ovarian cancer, RASSF and GST genes, methylation, chemotherapy, remission duration, recurrence frequency.